Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer

LIMITing tumours with an immunogenic lncRNA

Overcoming immune resistance mechanisms in patients with cancer is critical for successful immunotherapy. A new study now identifies LIMIT as an immunogenic long non-coding RNA (lncRNA) that intrinsically regulates anti-tumour immune responses, thereby highlighting the therapeutic potential of targeting lncRNAs to improve the outcome of cancer immunotherapy.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: LncRNAs modulate antitumour immune responses.

References

  1. 1.

    Frankish, A. et al. Nucleic Acids Res. 47, D766–D773 (2019).

    CAS  Article  Google Scholar 

  2. 2.

    Schmitt, A. M. & Chang, H. Y. Cancer Cell 29, 452–463 (2016).

    CAS  Article  Google Scholar 

  3. 3.

    Huarte, M. Nat. Med. 21, 1253–1261 (2015).

    CAS  Article  Google Scholar 

  4. 4.

    Gaopeng, L. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-021-00672-3 (2021).

  5. 5.

    Hezroni, H. et al. Cell Reports 11, 1110–1122 (2015).

    CAS  Article  Google Scholar 

  6. 6.

    Hu, Q. et al. Nat. Immunol. 20, 835–851 (2019).

    CAS  Article  Google Scholar 

  7. 7.

    Wang, Q. M., Lian, G. Y., Song, Y., Huang, Y. F. & Gong, Y. Life Sci. 231, 116335 (2019).

    CAS  Article  Google Scholar 

  8. 8.

    Gil, N. & Ulitsky, I. Nat. Rev. Genet. 21, 102–117 (2020).

    CAS  Article  Google Scholar 

  9. 9.

    Chen, Y. G., Satpathy, A. T. & Chang, H. Y. Nat. Immunol. 18, 962–972 (2017).

    CAS  Article  Google Scholar 

  10. 10.

    Zhang, L., Xu, X. & Su, X. Mol. Cancer 19, 48 (2020).

    Article  Google Scholar 

  11. 11.

    Carpenter, S. et al. Science 341, 789–792 (2013).

    CAS  Article  Google Scholar 

  12. 12.

    Kalbasi, A. & Ribas, A. Nat. Rev. Immunol. 20, 25–39 (2020).

    CAS  Article  Google Scholar 

  13. 13.

    Hou, J. et al. J. Immunother. Cancer 9, e001819 (2021).

    Article  Google Scholar 

  14. 14.

    Tawbi, H. et al. J. Clin. Oncol. 36, TPS9596 (2018).

    Article  Google Scholar 

  15. 15.

    Ribas, A. et al. Nat. Commun. 11, 6262 (2020).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Weiyi Peng.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hou, J., Peng, W. LIMITing tumours with an immunogenic lncRNA. Nat Cell Biol 23, 443–445 (2021). https://doi.org/10.1038/s41556-021-00682-1

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing